Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Liselot Mus is active.

Publication


Featured researches published by Liselot Mus.


Nature Methods | 2017

EV-TRACK: transparent reporting and centralizing knowledge in extracellular vesicle research

Jan Van Deun; Pieter Mestdagh; Patrizia Agostinis; Özden Akay; Sushma Anand; Jasper Anckaert; Zoraida Andreu Martinez; Tine Baetens; Els Beghein; Laurence Bertier; Geert Berx; Janneke Boere; Stephanie Boukouris; Michel Bremer; Dominik Buschmann; James Brian Byrd; Clara Casert; Lesley Cheng; Anna Cmoch; Delphine Daveloose; Eva De Smedt; Seyma Demirsoy; Victoria Depoorter; Bert Dhondt; Tom A. P. Driedonks; Aleksandra M. Dudek; Abdou ElSharawy; Ilaria Floris; Andrew D. Foers; Kathrin Gärtner

We argue that the field of extracellular vesicle (EV) biology needs more transparent reporting to facilitate interpretation and replication of experiments. To achieve this, we describe EV-TRACK, a crowdsourcing knowledgebase (http://evtrack.org) that centralizes EV biology and methodology with the goal of stimulating authors, reviewers, editors and funders to put experimental guidelines into practice.


Scientific Reports | 2016

Depletion of tRNA-halves enables effective small RNA sequencing of low-input murine serum samples

Alan Van Goethem; Nurten Yigit; Celine Everaert; Myrthala Moreno-Smith; Liselot Mus; Eveline Barbieri; Frank Speleman; Pieter Mestdagh; Jason M. Shohet; Tom Van Maerken; Jo Vandesompele

The ongoing ascent of sequencing technologies has enabled researchers to gain unprecedented insights into the RNA content of biological samples. MiRNAs, a class of small non-coding RNAs, play a pivotal role in regulating gene expression. The discovery that miRNAs are stably present in circulation has spiked interest in their potential use as minimally-invasive biomarkers. However, sequencing of blood-derived samples (serum, plasma) is challenging due to the often low RNA concentration, poor RNA quality and the presence of highly abundant RNAs that dominate sequencing libraries. In murine serum for example, the high abundance of tRNA-derived small RNAs called 5′ tRNA halves hampers the detection of other small RNAs, like miRNAs. We therefore evaluated two complementary approaches for targeted depletion of 5′ tRNA halves in murine serum samples. Using a protocol based on biotinylated DNA probes and streptavidin coated magnetic beads we were able to selectively deplete 95% of the targeted 5′ tRNA half molecules. This allowed an unbiased enrichment of the miRNA fraction resulting in a 6-fold increase of mapped miRNA reads and 60% more unique miRNAs detected. Moreover, when comparing miRNA levels in tumor-carrying versus tumor-free mice, we observed a three-fold increase in differentially expressed miRNAs.


Journal of Visualized Experiments | 2015

Chick Heart Invasion Assay for Testing the Invasiveness of Cancer Cells and the Activity of Potentially Anti-invasive Compounds

Marc Bracke; Bart Roman; Christian V. Stevens; Liselot Mus; Virinder S. Parmar; Olivier De Wever; Marc M. Mareel

The goal of the chick heart assay is to offer a relevant organ culture method to study tumor invasion in three dimensions. The assay can distinguish between invasive and non-invasive cells, and enables study of the effects of test compounds on tumor invasion. Cancer cells - either as aggregates or single cells - are confronted with fragments of embryonic chick heart. After organ culture in suspension for a few days or weeks the confronting cultures are fixed and embedded in paraffin for histological analysis. The three-dimensional interaction between the cancer cells and the normal tissue is then reconstructed from serial sections stained with hematoxylin-eosin or after immunohistochemical staining for epitopes in the heart tissue or the confronting cancer cells. The assay is consistent with the recent concept that cancer invasion is the result of molecular interactions between the cancer cells and their neighbouring stromal host elements (myofibroblasts, endothelial cells, extracellular matrix components, etc.). Here, this stromal environment is offered to the cancer cells as a living tissue fragment. Supporting aspects to the relevance of the assay are multiple. Invasion in the assay is in accordance with the criteria of cancer invasion: progressive occupation and replacement in time and space of the host tissue, and invasiveness and non-invasiveness in vivo of the confronting cells generally correlates with the outcome of the assay. Furthermore, the invasion pattern of cells in vivo, as defined by pathologists, is reflected in the histological images in the assay. Quantitative structure-activity relation (QSAR) analysis of the results obtained with numerous potentially anti-invasive organic congener compounds allowed the study of structure-activity relations for flavonoids and chalcones, and known anti-metastatic drugs used in the clinic (e.g., microtubule inhibitors) inhibit invasion in the assay as well. However, the assay does not take into account immunological contributions to cancer invasion.


PLOS ONE | 2018

Vehicle development, pharmacokinetics and toxicity of the anti-invasive agent 4-fluoro-3’,4’,5’-trimethoxychalcone in rodents

Liselot Mus; Geertrui Denecker; Frank Speleman; Bart Roman

Effective inhibitors of invasion and metastasis represent a serious unmet clinical need. We have recently identified 4-fluoro-3’,4’,5’-trimethoxychalcone or C16 as a potent anti-invasive molecule. In this paper, we report on the development of an optimized vehicle for oral administration of C16. We also explore its pharmacokinetic and toxicity profile in rodents as a prelude to a broad-scope evaluation as a pharmacological tool in animal models of disease. C16 showed suboptimal pharmacokinetics with limited oral bioavailability and whole blood stability. Rapid metabolism with elimination via glutathione conjugation was observed. An oral dosing routine using medicated gels was developed to overcome bioavailability issues and yielded sustained whole blood levels above the half maximal effective concentration (EC50) in a 7-day study. The compound proved well-tolerated in acute and chronic experiments at 300 mg/kg PO dosing. The medicated gel formulation is highly suitable for evaluation of C16 in animal models of disease.


Advances in Neuroblastoma Research, Congress abstracts | 2018

Exploring the contribution of gene dosage effects of 17Q gain on ESC and neuroblastoma proliferation

Liselot Mus; Geertrui Denecker; Nadja Zeltner; Yudelca Ogando; Stéphane Van Haver; Ellen Sanders; Eva Jacobs; Mina Popovic; Christophe Van Neste; Suzanne Vanhauwaert; Kaat Durinck; Björn Menten; Katleen De Preter; Björn Heindryckx; Lorenz Studer; Stephen S. Roberts; Franki Speleman


18th Annual BeSHG meeting: The epigenome in development and disease | 2018

Exploring the contribution of gene dosage effects of 17q gain on ESC and neuroblastoma proliferation

Liselot Mus; Geertrui Denecker; Nadja Zeltner; Yudelca Ogando; Stéphane Van Haver; Ellen Sanders; Eva Jacobs; Mina Popovic; Christophe Van Neste; Suzanne Vanhauwaert; Kaat Durinck; Björn Menten; Katleen De Preter; Björn Heindryckx; Lorenz Studer; Stephen S. Roberts; Franki Speleman


student research symposium | 2017

The ETV5 oncogene is a target of activated ALK signaling in neuroblastoma

Liselot Mus; Irina Lambertz; Candy Kumps; Shana Claeys; Geertrui Denecker; Wouter Van Loocke; Christophe Van Neste; Jan Koster; Rogier Versteeg; Nadine Van Roy; Bram De Wilde; Genevieve Laureys; Johannes H. Schulte; Olivier De Wever; Katleen De Preter; Franki Speleman


OncoPoint, 4th Research seminar, Abstracts | 2016

ETV5 functionally connects ALK and CXCR4 signaling in neuroblastoma

Irina Lambertz; Liselot Mus; Candy Kumps; Shana Claeys; Nadine Van Roy; Bram De Wilde; Genevieve Laureys; Johannes Shulte; Olivier De Wever; Katleen De Preter; Franki Speleman


OncoPoint, 4th Research seminar, Abstracts | 2016

Dual targeting of ALK and RET: establishing a novel basis for the treatment of neuroblastoma

Liselot Mus; Shana Claeys; Bram De Wilde; Genevieve Laureys; Alan Van Goethem; Johannes H. Schulte; Katleen De Preter; Irina Lambertz; Franki Speleman


EU COST Action CA15135 'MuTaLig', 1st Annual meeting, Abstracts | 2016

Discovery and development of new anti-invasive agents, an unmet clinical need

Bart Roman; Liselot Mus; Tine De Ryck; Marc Bracke; Christian V. Stevens

Collaboration


Dive into the Liselot Mus's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Irina Lambertz

Ghent University Hospital

View shared research outputs
Top Co-Authors

Avatar

Shana Claeys

Ghent University Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Candy Kumps

Ghent University Hospital

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge